awmsg logo



emtricitabine/rilpivirine/tenofovir disoproxil (as fumarate) (Eviplera®)


Reference No. 880

Publication date:
13/08/2012


Last review date:
30/08/2016

Appraisal information

emtricitabine/rilpivirine/tenofovir disoproxil (as fumarate) (Eviplera®) 200 mg/25 mg/245 mg film-coated tablet


Company: Gilead Sciences Ltd
BNF category: Infections
NMG meeting date: 12/06/2012
AWMSG meeting date: 18/07/2012
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 1412
Ministerial ratification: 07/08/2012

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Emtricitabine/rilpivirine/tenofovir (Eviplera®) is recommended as an option for use within NHS for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naive adult patients with a viral load ≤ 100,000 HIV-1 RNA copies/ml.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download